Norges Bank Alaunos Therapeutics, Inc. Transaction History

Norges Bank

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 08, 2019	SELL	$1.61 - $3.62 $337,910 - $759,772	-209,882 Closed	0 $0
Q3 2018 Nov 12, 2019	BUY	$2.26 - $3.27 $474,333 - $686,314	209,882 New	209,882 $671,000
Q3 2018 Nov 09, 2018	SELL	$2.26 - $3.27 $1.24 Million - $1.79 Million	-548,865 Closed	0 $0
Q2 2018 Aug 12, 2019	BUY	$3.02 - $4.94 $1.66 Million - $2.71 Million	548,865 New	548,865 $1.66 Million
Q2 2018 Jul 23, 2018	SELL	$3.02 - $4.94 $2.47 Million - $4.05 Million	-818,865 Closed	0 $0
Q1 2018 May 15, 2019	BUY	$3.46 - $5.14 $2.83 Million - $4.21 Million	818,865 New	818,865 $3.21 Million
Q1 2018 May 09, 2018	SELL	$3.46 - $5.14 $2.83 Million - $4.21 Million	-818,865 Closed	0 $0
Q4 2017 Mar 05, 2018	BUY	$4.0 - $6.54 $3.28 Million - $5.36 Million	818,865 New	818,865 $3.39 Million
Q4 2017 Feb 09, 2018	SELL	$4.0 - $6.54 $3.28 Million - $5.36 Million	-818,865 Closed	0 $0
Q3 2017 Nov 13, 2018	BUY	$4.99 - $6.57 $4.09 Million - $5.38 Million	818,865 New	818,865 $5.03 Million
Q3 2017 Nov 07, 2017	SELL	$4.99 - $6.57 $4.09 Million - $5.38 Million	-818,865 Closed	0 $0
Q2 2017 Jul 24, 2018	SELL	N/A	-219,663 Reduced 21.15%	818,865 $5.09 Million
Q3 2016 Nov 13, 2017	BUY	N/A	1,038,528	1,038,528 $0

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $443M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

Stay updated on Norges Bank with notifications on news.